bioAffinity Technologies Closes $4M Direct Stock Offering via WallachBeth
bioAffinity Technologies raised $4 million through a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.
WallachBeth Capital LLC announced the successful closing of a $4 million registered direct financing of common stock for bioAffinity Technologies, Inc., a Nasdaq-listed biotechnology firm focused on noninvasive healthcare solutions. The offering was priced at-the-market in compliance with Nasdaq listing rules and was accompanied by a concurrent private placement.
bioAffinity Technologies trades on the Nasdaq exchange under the ticker symbols BIAF and BIAFW. The company is engaged in developing diagnostic and therapeutic tools aimed at detecting disease through noninvasive methods, positioning it within a competitive segment of the biotechnology sector.
Read more Abrdn Closed-End Funds Announce October Distributions →
WallachBeth Capital, headquartered in Jersey City, N.J., served as the placement agent for the transaction. The firm describes itself as a leading provider of capital markets and institutional execution services, and the bioAffinity deal represents a typical at-the-market structured raise that allows companies to access equity capital without the deep discount often associated with traditional follow-on offerings.
Registered direct offerings paired with concurrent private placements have become a common mechanism for small-cap biotech companies seeking to raise capital efficiently. By pricing at-the-market under Nasdaq rules, bioAffinity avoided the dilutive pressure that can accompany below-market issuances, though the ultimate impact on existing shareholders will depend on how proceeds are deployed.
The announcement was made October 9, 2026. No use of proceeds was detailed in the available release language. Continue reading at Banking & Financial Services.
